Trial Title:
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
NCT ID:
NCT05526989
Condition:
Penile Carcinoma
Conditions: Official terms:
Carcinoma
Penile Neoplasms
Niraparib
Dostarlimab
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Dostarlimab
Description:
300 mg Dostarlimb will be administered by IV, increasing to 1000 mg after cycle 4.
Arm group label:
Dostarlimab and Niraparib treatment
Other name:
Jemperli
Intervention type:
Drug
Intervention name:
Niraparib
Description:
200 mg Niraparib will be taken once daily by mouth days 1-21 of all cycles.
Arm group label:
Dostarlimab and Niraparib treatment
Other name:
Zejula
Summary:
The purpose of the study is to evaluate the efficacy and safety of the combination of
niraparib and dostarlimab in patients participants with advanced relapsed/refractory
penile cancer.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Provide written, informed consent to participate in the study and follow the study
procedures
- Histologically confirmed stage III (unresectable) or stage IV penile cancer, as per
American Joint Committee on Cancer (AJCC) staging system.
- Life expectancy >12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1 (ECOG
performance status 2 can be included after discussion with PI)
- Measurable disease per iRECIST
- Participants who have progressed or had tolerance problems to no more than one prior
line of therapy in the locally advanced setting or post platinum-based chemotherapy,
including in a neoadjuvant or adjuvant setting or in combination with radiation
therapy.
- Participants must not have received any prior immune-oncology regimens, including
but not limited to checkpoint inhibitors such as anti-PD-1, anti-PD-L1, anti-PD-L2,
anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically
targeting T cell co-stimulation or checkpoint pathways, indoleamine 2,3-dioxygenase
pathway inhibitors, cancer vaccines, adoptive cell therapies, or other cytokine
therapies
- Demonstrated adequate organ function, as defined in protocol, within 28 days of
treatment initiation
- Clinically significant toxic effect(s) of the most recent prior chemotherapy must be
Grade 1 or resolved (except alopecia and sensory neuropathy that may be Grade 2).
- If the participant received major surgery or radiation therapy of > 30 Gy, they must
have recovered from the toxicity and/or complications from the intervention.
- Participants and their female partners of childbearing potential must agree and
commit to use a highly effective form of contraception (e.g., condom with
spermicidal foam/gel/film/cream/suppository) throughout the duration of the study
until 6 months (female participants) and 3 months (male participants and their
female partners), respectively, following the last dose of study drug. Female
partner may use either an intrauterine device or hormonal contraception and continue
until 3 months following the last dose of study drug. This criterion may be waived
for male patients who have had a vasectomy 90 days months before signing the
informed consent form (ICF) or a penectomy.
- Participants must not have known active brain metastases.
- Participants with treated brain metastases are eligible if they have neurologically
returned to baseline (except for residual signs or symptoms related to the cns
treatment) for at least 4 weeks prior to the first dose of study drug(s).
- Participant cannot be receiving any chronic systemic steroids (prednisone or
equivalent) > 20 mg daily, for at least 4 weeks prior to the first dose of study
drug(s).
- Participants with small, untreated, asymptomatic central nervous system (CNS)
metastases without associated edema, shift, or requirement for steroids are eligible
after discussion with the Medical Monitor, i.e. the Principal Investigator.
- No stereotactic radiation or craniotomy within 4 weeks of Cycle 1 Day 1
- No new central nervous system lesions on repeat radiographic imaging 4 weeks or more
from last treatment
- No clinically significant symptoms secondary to brain metastases
- Participants must also consent to allow acquisition of existing formalin-fixed
paraffin-embedded (FFPE) material (archival tumor tissue), either a block or
unstained slides for planned correlative studies.
Exclusion Criteria:
- Use of an investigational agent or an investigational device within 4 weeks or
within a time interval less than at least 5 half-lives of the investigational agent,
whichever is shorter, before administration of first dose of study drug.
- Active, known or suspected autoimmune disease requiring systemic treatment within
the past 2 months or a documented history of clinically severe autoimmune disease
that requires systemic steroids or immunosuppressive agents. (Exceptions include any
patient on 10 mg or less of prednisone or equivalent, patients with vitiligo,
hypothyroidism stable on hormone replacement, Type I diabetes, Graves' disease,
Hashimoto's disease, alopecia areata, eczema, or with PI approval.)
- History of allergy or hypersensitivity to study drug components
- History of organ transplant that requires use of immune suppressive agents
- Current active pneumonitis within 90 days of planned start of the study or a known
history of interstitial lung disease, drug-related pneumonitis, or radiation
pneumonitis requiring steroid treatment.
- Prior surgery or radiotherapy encompassing >20% of the bone marrow within 14 days of
therapy. Patients must have recovered from all radiation-related toxicities.
- Active infection requiring systemic therapy; a known history of active tuberculosis.
- Has known active hepatitis B virus (HBV) infection (e.g., hepatitis B surface
antigen [HBsAg] reactive) or hepatitis C virus (HCV) infection (e.g., HCV
ribonucleic acid [RNA] qualitative is detected)
- Has known immunodeficiency or active human immunodeficiency virus (HIV-1/2
antibodies) with CD 4 count < 400 for in the past 6 months.
- Prolonged corrected QT interval (QTcF) > 450 ms for men
- History of unstable or deteriorating cardiac disease within the previous 6 months
prior to screening including but not limited to the following:
1. Unstable angina or myocardial infarction
2. Congestive heart failure (New York Heart Association [NYHA] Class III or IV)
3. Uncontrolled clinically significant arrhythmias
- Systolic BP >140 mmHg or diastolic BP >90 mmHg that has not been adequately treated
or controlled. Need for > 2 antihypertensive medications for management of
hypertension (excluding diuretics)
- Must not have received a transfusion (platelets or red blood cells) ' 4 weeks prior
to initiating protocol therapy.
- Must not have received colony stimulating factors (e.g., granulocyte
colony-stimulating factor, granulocyte macrophage colony stimulating factor, or
recombinant erythropoietin) within 4 weeks prior initiating protocol therapy.
- Has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior
chemotherapy that persisted > 4 weeks and was related to the most recent treatment.
- Must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid
leukemia (AML)
- Has experienced a Grade 3 or greater immune-related Adverse Event with prior
immunotherapy, with the exception of non-clinically significant lab abnormalities.
- Has received a live vaccine within 30 days of initiating protocol therapy
Gender:
Male
Gender based:
Yes
Gender description:
males only
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Moffitt Cancer Center
Address:
City:
Tampa
Zip:
33612
Country:
United States
Status:
Recruiting
Contact:
Last name:
Robin Neubauer
Phone:
813-745-5604
Email:
Robin.Neubauer@moffitt.org
Investigator:
Last name:
Jad Chahoud, MD, MPH
Email:
Principal Investigator
Investigator:
Last name:
Juskaran Chadha, DO
Email:
Sub-Investigator
Investigator:
Last name:
Monica Chatwal, MD
Email:
Sub-Investigator
Investigator:
Last name:
Jingsong Zhang, MD, PhD
Email:
Sub-Investigator
Facility:
Name:
MD Anderson Cancer Center
Address:
City:
Houston
Zip:
77030
Country:
United States
Status:
Not yet recruiting
Contact:
Last name:
Curtis Pettaway, MD
Phone:
713-792-3250
Email:
cpettawa@mdanderson.org
Investigator:
Last name:
Curtis Pettaway, MD
Email:
Principal Investigator
Start date:
December 28, 2022
Completion date:
October 2026
Lead sponsor:
Agency:
H. Lee Moffitt Cancer Center and Research Institute
Agency class:
Other
Collaborator:
Agency:
GlaxoSmithKline
Agency class:
Industry
Source:
H. Lee Moffitt Cancer Center and Research Institute
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05526989
https://www.moffitt.org/clinical-trials-research/clinical-trials/
